Doxorubicin inhibits TGF-beta signaling in human lung carcinoma A549 cells.

@article{Filyak2008DoxorubicinIT,
  title={Doxorubicin inhibits TGF-beta signaling in human lung carcinoma A549 cells.},
  author={Yevhen Filyak and Oksana Filyak and Serhiy Souchelnytskyi and Rostyslav R Stoika},
  journal={European journal of pharmacology},
  year={2008},
  volume={590 1-3},
  pages={67-73}
}
Doxorubicin is a DNA-damaging drug, commonly used for treatment of cancer patients. Doxorubicin causes not only cytotoxic and cytostatic effects, but also inhibits metastasis formation, while TGFbeta1 (Transforming Growth Factor-beta1) is a cytokine that is often up-regulated in human cancers and can promote metastasis formation. We have studied the influence of Doxorubicin on TGFbeta signaling in tumor cells. Here we have demonstrated that Doxorubicin inhibited TGFbeta-signaling in human lung… CONTINUE READING